Ravi Chandra, M.D., Ph.D. is an Assistant Professor of Radiation Medicine. He serves as the department’s inaugural director of interprofessional education, the associate director of the residency program, and a block director within the undergraduate medical curriculum in the OHSU School of Medicine. Dr. Chandra also is a member of the Translational Oncology Program at the Knight Cancer Institute. He is a frequently invited speaker and actively involved in professional, resident, and medical student education. He completed his residency and clinical fellowship at the Harvard Radiation Oncology Program. Dr. Chandra received degrees from Johns Hopkins (MD), UC-Berkeley (PhD-Chemistry), and Stanford (BS-Chemistry and Biology).
Dr. Chandra maintains clinical and scholarly work involving Head & Neck and CNS malignancies, in addition to projects on education and patient experience/quality. He has performed and published in the areas of basic (lab), translational, and clinical oncology research.
He is particularly passionate about providing shadowing and mentorship opportunities for students of all ages, especially those from diverse backgrounds.
Learn more about Dr. Chandra here.
- Cooperative and institutional clinical trials
- Translation of basic science technologies to the clinic (biomarkers, imaging agents, immunotherapy)
- Retrospective studies including case series/institutional experience
- Interprofessional and medical trainee education
- Writing and editing of textbooks
- Digital/telehealth opportunities
- Role of radiation staff in patient education
- Electronic and otheratient education materials
- Christopher Deig, M.D. (OHSU Radiation Oncology Resident)
- Cymon Kersch (OHSU M.D./Ph.D. Student)
- Taryn Norris (OHSU M.D. Student)
- Michael Lee (Camas High School Student)
- Ryan Li, M.D. (OHSU)
- Shannon Nugent, Ph.D. (OHSU/VA)
- Dan Golden, M.D., MHPE (University of Chicago)
- Jon Schoenfeld, M.D., MPH (Dana-Farber Cancer Institute/Harvard Medical School)
- Lior Braunstein, M.D. (Memorial Sloan Kettering Cancer Center)
- Kristi Tonning, M.S., RTT (OHSU)
- Katie Keane, M.D. (Massachusetts General Hospital/Harvard Medical School)
Chandra RA, Thomas CR. What Happens Next: Radiation Oncology After COVID?Clinical & Translational Radiation Oncology. 26 May 2020. doi: https://doi.org/10.1016/j.ctro.2020.05.009
Miller MA, Chandra RA, Cuccarese MF, Pfirschke C, Engblom C, Stapleton S, Adhikary U, Kohler RH, Mohan JF, Pittet MJ, Weissleder, R. Radiation Therapy Primes Tumors for Nanotherapeutic Delivery Via Macrophage-Mediated Vascular Bursts. Science Translational Medicine. 2017; 9(392): eaal0225: 12pp. (DOI: 10.1126/scitranslmed.aal0225).
Chandra RA*, Wilhite TJ*, Balboni TA, Alexander BM, Spektor A, Ott PA, Ng AK, Hodi FS, Schoenfeld JD. A Systematic Evaluation of Abscopal Responses Following Radiotherapy in Patients With Metastatic Melanoma Treated With Ipilimumab. Oncoimmunology. 2015; 4(11): e1046028: 7 pp. (DOI: 10.1080/2162402X.2015.1046028).
Chandra RA. Recognizing the Role of Bias in Patient Decision Making. Contemporary Oncology. 2014; 6(4): 6-8.
Chandra RA, Douglas ES, Mathies RA, Bertozzi CR, Francis MB. Programmable Cell Adhesion Encoded by DNA Hybridization. Angewandte Chemie International Edition. 2006; 45(6):896-901.